Common Stock Valuation Ratios (Price Multiples)
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Valuation Ratios
Regeneron Pharmaceuticals Inc., current price multiples
| Regeneron Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | Health Care | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||
| Current share price (P) | |||||||||||||||||
| No. shares of common stock outstanding | |||||||||||||||||
| Growth rate (g) | |||||||||||||||||
| Earnings per share (EPS) | |||||||||||||||||
| Next year expected EPS | |||||||||||||||||
| Operating profit per share | |||||||||||||||||
| Sales per share | |||||||||||||||||
| Book value per share (BVPS) | |||||||||||||||||
| Valuation Ratios (Price Multiples) | |||||||||||||||||
| Price to earnings (P/E) | |||||||||||||||||
| Price to next year expected earnings | |||||||||||||||||
| Price-earnings-growth (PEG) | |||||||||||||||||
| Price to operating profit (P/OP) | |||||||||||||||||
| Price to sales (P/S) | |||||||||||||||||
| Price to book value (P/BV) | |||||||||||||||||
Based on: 10-K (reporting date: 2024-12-31).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Regeneron Pharmaceuticals Inc., historical price multiples
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Price to earnings (P/E) | ||||||
| Price to operating profit (P/OP) | ||||||
| Price to sales (P/S) | ||||||
| Price to book value (P/BV) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Price to Earnings (P/E) Ratio
-
The price to earnings ratio exhibited notable volatility over the observed periods. Starting at 15.09 in 2020, it declined significantly to 8.37 in 2021, indicating a potential undervaluation or improved earnings relative to price during that year. The ratio then experienced a sharp increase to 19.68 in 2022, followed by a further rise to 25.99 in 2023, suggesting increased investor optimism or possibly elevated price levels relative to earnings. In 2024, the P/E ratio decreased again to 17.76, signaling a moderation in valuation.
- Price to Operating Profit (P/OP) Ratio
-
The P/OP ratio mirrored the trend observed in the P/E ratio, beginning at 14.82 in 2020 and dropping to a low of 7.55 in 2021. Subsequently, it climbed to 18.01 in 2022 and rose further to 25.39 by 2023, indicating similar shifts in valuation measures based on operating profitability. By 2024, the P/OP ratio decreased to 19.63, reflecting a slight correction but remaining elevated compared to earlier years.
- Price to Sales (P/S) Ratio
-
The price to sales ratio demonstrated fluctuation with tendencies resembling the other valuation ratios but with less pronounced extremes. From 6.24 in 2020, it fell to 4.20 in 2021, suggesting a more attractive valuation on sales basis during that year. It then increased to 7.01 in 2022 and peaked at 7.84 in 2023, showing heightened valuation levels. By 2024, the ratio decreased to 5.52, indicating a degree of valuation normalization.
- Price to Book Value (P/BV) Ratio
-
The P/BV ratio showed a general downward trend over the period. It started at 4.81 in 2020 and decreased to 3.60 in 2021. This was followed by a moderate increase to 3.77 in 2022 and a slight rise to 3.96 in 2023. The ratio then declined more substantially to 2.67 in 2024. The overall pattern suggests diminishing market valuation relative to book value over time, with a temporary stabilization around 2022-2023.
Price to Earnings (P/E)
Regeneron Pharmaceuticals Inc., historical P/E calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Net income (in thousands) | ||||||
| Earnings per share (EPS)2 | ||||||
| Share price1, 3 | ||||||
| Valuation Ratio | ||||||
| P/E ratio4 | ||||||
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| P/E Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| P/E Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Data adjusted for splits and stock dividends.
2 2024 Calculation
EPS = Net income ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
4 2024 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
- Share Price
- The share price of the company exhibited a strong upward trend from 2020 to 2023, increasing from $494.90 to $936.33. This represents a nearly 89% appreciation over the three-year period. However, in 2024, the share price declined to $716.72, indicating a significant pullback of approximately 23.5% from the previous year.
- Earnings per Share (EPS)
- EPS showed substantial volatility during the period. Starting at $32.79 in 2020, EPS more than doubled to $74.40 in 2021, indicating a sharp improvement in profitability. This was followed by a significant decline to $39.68 in 2022, and a further modest decrease to $36.02 in 2023. In 2024, EPS rebounded slightly to $40.36, suggesting some recovery but remaining well below the peak observed in 2021.
- Price-to-Earnings (P/E) Ratio
- The P/E ratio reflects the market valuation relative to earnings and fluctuated notably across the period. It was 15.09 in 2020, then decreased substantially to 8.37 in 2021, coinciding with the peak in EPS. The ratio increased sharply to 19.68 in 2022 as EPS dropped, followed by a further rise to 25.99 in 2023, despite the decline in EPS during these years. In 2024, the P/E ratio decreased to 17.76, consistent with the partial recovery in EPS and the fall in share price.
- Overall Insights
- The data indicates that the company's market price and earnings performance experienced pronounced fluctuations over the five-year span. The share price increased steadily until 2023, supported by varying EPS levels. EPS peaked in 2021, then declined before stabilizing somewhat in 2024. P/E ratios varied inversely with EPS movements, reflecting changing market perceptions of the company's valuation relative to earnings. The decline in share price and P/E ratio in 2024 suggests a market reassessment, possibly in response to the earlier volatility in earnings performance.
Price to Operating Profit (P/OP)
Regeneron Pharmaceuticals Inc., historical P/OP calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Income from operations (in thousands) | ||||||
| Operating profit per share2 | ||||||
| Share price1, 3 | ||||||
| Valuation Ratio | ||||||
| P/OP ratio4 | ||||||
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| P/OP Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| P/OP Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Data adjusted for splits and stock dividends.
2 2024 Calculation
Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
4 2024 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
- Share Price
- The share price exhibited a consistent upward trend from 2020 through 2023, rising from $494.90 to a peak of $936.33. However, in 2024, the share price declined to $716.72, reflecting a notable decrease after several years of growth.
- Operating Profit per Share
- Operating profit per share showed significant variability during the period. Starting at $33.39 in 2020, it more than doubled to $82.43 in 2021, followed by a sharp decline to $43.35 in 2022. It continued to decrease gradually in 2023 and 2024, settling at approximately $36.50, which is slightly above the 2020 level but substantially below the 2021 peak.
- Price-to-Operating-Profit (P/OP) Ratio
- The P/OP ratio declined markedly from 14.82 in 2020 to a low of 7.55 in 2021, indicating that the share price was relatively undervalued compared to operating profit at that time. Subsequently, the ratio increased sharply, reaching 18.01 in 2022, then rising further to 25.39 in 2023. In 2024, it decreased somewhat to 19.63, though still above the earlier years except 2022. This suggests fluctuating investor valuation relative to operating profit, with a particularly high emphasis on share price in 2023.
- Overall Insights
- The data reveals a period of strong share price growth through 2023, contrasted by a peak and subsequent decline in operating profit per share after 2021. The P/OP ratio fluctuations indicate varying market sentiment and valuation over time, with the ratio peaking when operating profit declined but share price rose. The decrease in share price in 2024 alongside a stable but lower operating profit per share could indicate market adjustments to profitability levels or external factors affecting investor confidence.
Price to Sales (P/S)
Regeneron Pharmaceuticals Inc., historical P/S calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Revenues (in thousands) | ||||||
| Sales per share2 | ||||||
| Share price1, 3 | ||||||
| Valuation Ratio | ||||||
| P/S ratio4 | ||||||
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| P/S Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| P/S Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Data adjusted for splits and stock dividends.
2 2024 Calculation
Sales per share = Revenues ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
4 2024 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
- Share Price Trend
- The share price exhibited a general upward trajectory from 2020 to 2023, increasing steadily from $494.9 to $936.33. However, in 2024, there was a notable decline to $716.72, indicating a significant correction after a period of growth.
- Sales Per Share Trend
- Sales per share showed considerable volatility during the observed period. From $79.31 in 2020, sales more than doubled to $148.07 in 2021. This was followed by a substantial decrease to $111.35 in 2022. Subsequently, sales per share resumed growth, climbing to $129.91 by 2024, suggesting recovery and improvement after the dip in 2022.
- Price-to-Sales (P/S) Ratio Trend
- The P/S ratio, reflecting market valuation relative to sales, fluctuated notably across the years. It decreased from 6.24 in 2020 to 4.2 in 2021 despite rising sales per share, implying that the market valuation did not keep pace with sales growth that year. The ratio then increased sharply to 7.84 in 2023, the highest in the period, pointing toward growing investor optimism or higher valuation multiples. By 2024, the P/S ratio declined again to 5.52, evidencing a market re-rating consistent with the share price decrease.
- Overall Insights
- The financial data reflect a period of strong growth followed by market readjustment. While sales per share experienced a dip in 2022, recovery was evident in subsequent years. The share price followed a similar pattern but showed a sharper correction in 2024. The P/S ratio's fluctuations suggest changing investor sentiment and valuation approaches throughout the period, aligning with the broader shifts in market pricing relative to sales performance.
Price to Book Value (P/BV)
Regeneron Pharmaceuticals Inc., historical P/BV calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Stockholders’ equity (in thousands) | ||||||
| Book value per share (BVPS)2 | ||||||
| Share price1, 3 | ||||||
| Valuation Ratio | ||||||
| P/BV ratio4 | ||||||
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| P/BV Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| P/BV Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Data adjusted for splits and stock dividends.
2 2024 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
4 2024 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
The data reveals several important trends regarding the financial valuation and market perception of the company over the analyzed five-year period.
- Share Price
- The share price exhibited a consistent upward trend from 2020 to 2023, increasing from $494.9 to $936.33. However, in 2024, there was a noticeable decline to $716.72, indicating a reduced market valuation relative to the peak experienced the prior year.
- Book Value per Share (BVPS)
- BVPS showed a steady and continuous increase throughout the entire period, rising from $102.91 in 2020 to $268.5 in 2024. This suggests ongoing growth in the company's net asset value on a per-share basis, reflecting potentially strengthened equity and accumulation of retained earnings or other comprehensive income gains.
- Price-to-Book Value Ratio (P/BV)
- The P/BV ratio trended downward overall, starting at 4.81 in 2020 and falling to 2.67 in 2024. Notably, there was a significant drop between 2023 and 2024 (from 3.96 to 2.67), coinciding with the decline in the share price despite continuous growth in book value. This pattern indicates that the market's premium over the book value per share diminished over time, suggesting either increasing investor caution or revaluation of the company's growth prospects.
In summary, the steady increase in book value per share indicates strengthening fundamental financial metrics, while the share price fluctuation and declining P/BV ratio in 2024 reflect changing market sentiment and valuation multiples. The divergence between rising book value and a declining market price in the latest year could warrant further investigation into operating performance, market conditions, or external factors influencing investor confidence.